Contact
Please use this form to send email to PR contact of this press release:
BioStem Technologies (BSEM) Subsidiary Nesvik Pharmaceuticals Announces the Completion of An Asset Purchase of Multiple New Drug Compounds and Launches Joint Development Venture with CCM Pharma Solutions
TO: